Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial)
{{output}}
Background: Despite advances in multimodal therapy, high-risk neuroblastoma (HR-NB) continues to have poor outcomes. Response to induction chemotherapy is a key predictor of long-term survival, yet intensive multi-agent regimens ... ...
